News from ambrx, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 17, 2016, 05:00 ET Ambrx's Innovative Antibody Drug Conjugate (ADC) US IND Active

Ambrx announced today that their ARX788 US IND is now active. ARX788 is Ambrx's most advanced internally developed site-specific ADC targeting...


Aug 04, 2016, 09:00 ET Ambrx closes $45M round of financing

 Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein...


Mar 21, 2016, 20:00 ET Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients

 Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) announced today that they initiated First-In-Human phase I clinical trial with ARX788, Ambrx's most...


Nov 16, 2015, 10:22 ET Ambrx Announces New Chief Medical Officer

 Ambrx today announced the appointment of Yong-Jiang Hei, M.D., Ph.D. as Chief Medical Officer (CMO) reporting directly to CEO, Tiecheng "Alex"...


May 21, 2015, 19:00 ET Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx

A consortium ("the Consortium") consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China...